Background/Aims: Glucocorticoids-induced abnormal glucose metabolism (AGM) is a common medical problem in patients with non-diabetic chronic kidney disease (CKD). However, little information is available regarding the prediction of steroid-induced AGM in this patient population. Methods: In this prospective cohort study, we consecutively enrolled 303 non-diabetic CKD patients with fasting plasma glucose (FPG) levels <5.6 mmol/l and normal oral glucose tolerance test (OGTT). OGTT was performed every 3 months during glucocorticoid treatment to identify new-onset AGM, and patients were followed for 12 months post steroid withdrawal. Results: During 593 person-years, there were 107 incident cases of steroid-induced AGM (18/100 person-year), including 55 (51.4%) diabetes and 52 (48.6%) pre-diabetes. In a multivariate model, each millimole increase per liter in FPG enhanced the risk of AGM by 4.6-fold (hazard ratio 4.58, 95% confidence interval, 2.67-7.83). After adjusting other risk factors, a progressively increased risk of AGM or DM was observed in patients with FPG levels ≥4.8 mmol/l, as compared with those whose levels were ≤4.3 mmol/l (p for trend <0.001). Furthermore, a greater increase in FPG level (≥0.3 mmol/l) during the first 3 months of glucocorticoid treatment was associated with an increased risk for future diabetes. For predicting steroid-induced diabetes, the area under the receiver-operating characteristic curve was 0.90 for the combination of FPG and changes in FPG levels at month 3. Conclusion: Higher-normal FPG and a greater increase in FPG levels during glucocorticoid treatment may help to identify non-diabetic CKD patients at increased risk of steroid-induced AGM or diabetes.

Keywords:
Steroid-induced diabetes, Non-diabetic CKD, Prediction, Risk factor
1.
Clore JN, Thurby-Hay L: Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15:469-474.
2.
Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall'Omo AM, Imbimbo B: An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983;72:1814-1820.
3.
Abdelmannan D, Tahboub R, Genuth S, Ismail-Beigi F: Effect of dexamethasone on oral glucose tolerance in healthy adults. Endocr Pract 2010;16:770-777.
4.
Kwon S, Hermayer KL: Glucocorticoid-induced hyperglycemia. Am J Med Sci 2013;345:274-277.
5.
Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA: Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 2006;12:358-362.
6.
Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R: Glucocorticoid-induced hyperglycemia. J Diabetes 2014;6:9-20.
7.
Chan HW, Cheung CY, Liu YL, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Li CS: Prevalence of abnormal glucose metabolism in Chinese renal transplant recipients: a single centre study. Nephrol Dial Transplant 2008;23:3337-3342.
8.
Panthakalam S, Bhatnagar D, Klimiuk P: The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004;49:139-141.
9.
Gulliford MC, Charlton J, Latinovic R: Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006;29:2728-2729.
10.
Valderhaug TG, Hjelmesaeth J, Rollag H, Leivestad T, Røislien J, Jenssen T, Hartmann A: Reduced incidence of new-onset posttransplantation diabetes mellitus during the last decade. Transplantation 2007;84:1125-1130.
11.
Bonato V, Barni R, Cataldo D, Collini A, Ruggieri G, De Bartolomeis C, Dotta F, Carmellini M: Analysis of posttransplant diabetes mellitus prevalence in a population of kidney transplant recipients. Transplant Proc 2008;40:1888-1890.
12.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:139-274.
13.
Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Koya D, Haneda M, Kashiwagi A, Yamauchi A: Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007;105:c54-c57.
14.
Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: global dimension and perspectives. Lancet 2013;382:260-272.
15.
Alberti KG, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-1062.
16.
Bargman JM: Management of minimal lesion glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999;70:S3-S16.
17.
Burgess E: Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999;70:S26-S32.
18.
Jindal KK: Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999;70:S33-S40.
19.
Levin A: Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int Suppl 1999;70:S41-S46.
20.
Muirhead N: Management of idiopathic membranous nephropathy: evidence-based recommendations. Kidney Int Suppl 1999;70:S47-S55.
21.
Nolin L, Courteau M: Management of IgA nephropathy: evidence-based recommendations. Kidney Int Suppl 1999;70:S56-S62.
22.
Bertsias G, Boumpas DT: Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol 2008;4:464-472.
23.
Bennett PH: The diagnosis of diabetes: new international classification and diagnostic criteria. Annu Rev Med 1983;34:295-309.
24.
Xu H, Lu Y, Teng D, Wang J, Wang L, Li Y: Assessment of glomerular filtration rate in renal transplant patients using serum cystatin C. Transplant Proc 2006;38:2006-2008.
25.
Mauck JC: The quantitation of urinary and spinal fluid proteins by a modified biuret method. Clin Biochem 1976;9:188-191.
26.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS: Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-29.
27.
Standards of medical care in diabetes - 2008. Diabetes Care 2008;31(suppl 1):S12-S54.
28.
Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J; InterASIA Collaborative Group: Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005;356:1398-1405.
29.
Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A: Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005;353:1454-1462.
30.
Hollingdal M, Juhl CB, Dall R, Sturis J, Veldhuis JD, Schmitz O, Pørksen N: Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 2002;45:49-55.
31.
Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997;99:414-423.
32.
Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, Hirsch IB: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004;27:553-591.
33.
Nichols GA, Hillier TA, Brown JB: Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. Am J Med 2008;121:519-524.
34.
Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23:1108-1112.
35.
Shaw JE, Zimmet PZ, Hodge AM, de Courten M, Dowse GK, Chitson P, Tuomilehto J, Alberti KG: Impaired fasting glucose: how low should it go? Diabetes Care 2000;23:34-39.
36.
Thomas GN, Chook P, Qiao M, Huang XS, Leong HC, Celermajer DS, Woo KS: Deleterious impact of ‘high normal' glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004;24:739-743.
37.
Kim DJ, Kim KW, Cho NH, Noh JH, Lee MS, Lee MK: The cutoff value of fasting plasma glucose to differentiate frequencies of cardiovascular risk factors in a Korean population. Diabetes Care 2003;26:3354-3356.
38.
Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI: Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991;254:573-576.
39.
Fliser D, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek E, Ritz E: Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998;53:1343-1347.
40.
Kato Y, Hayashi M, Ohno Y, Suzawa T, Sasaki T, Saruta T: Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis. Clin Nephrol 2000;54:366-373.
41.
Blackburn D, Hux J, Mamdani M: Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002;17:717-720.
42.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
43.
Flanigan MJ, Khairullah QT, Lim VS: Dialysate sodium delivery can alter chronic blood pressure management. Am J Kidney Dis 1997;29:383-391.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.